PDCD1 and B-cell chronic lymphocytic leukemia: Furthermore, several studies have shown a positive effect of BTKi on T-cell responses in CLL via enhanced T-cell diversity and effector function as well as improved antigen presentation, and reduced expression of programmed cell death protein 1 (PD1) and programmed cell death ligand 1 (PDL1) of leukemia cells (47–53).